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AmphetamineDeﬁcits in an operational measure of sensorimotor gating – the prepulse inhibition of startle (PPI) – are
presented in psychiatric disorders such as schizophrenia, bipolar disorder, and attention deﬁcit/hyperactivity
disorder (ADHD). Some previous studies showed that the spontaneously hypertensive rats (SHR) present PPI
deﬁcit. Although SHR is suggested as an animal model to study ADHD, we have suggested that the behavioral
phenotype of this strain mimics some aspects of schizophrenia. The aim of this study was to characterize the
PPI response in SHR. Pharmacological characterization consisted in the evaluation of the effects of the
following drugs administered to adult Wistar rats (WR) and SHR previously to the PPI test: amphetamine
(used for ADHD and also a psychotomimetic drug), haloperidol and clozapine (antipsychotic drugs),
metoclopramide (dopamine antagonist without antipsychotic properties) and carbamazepine (mood
stabilizer). Our results showed that SHR presented reduced PPI. This deﬁcit was similar to that induced by
amphetamine in WR. Only the atypical antipsychotic clozapine improved the PPI deﬁcit observed in SHR.
These ﬁndings reinforce the SHR strain as an animal model to study several aspects of schizophrenia,
including the abnormalities in sensorimotor gating associated with this disease.ity Disorder; AMPH, amphet-
zepine; CLO, Clozapine; HALO,
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Prepulse inhibition of startle (PPI) is characterized by the reduction
of an acoustic startle reﬂex to an intense acoustic stimulus (pulse)
when immediately preceded by a lower intensity stimulus (prepulse)
(Hoffman and Ison, 1980; Swerdlow et al., 2001). PPI is considered an
operational measure of sensorimotor gating and is extensively used in
translational models since it appears to be present in all mammals,
including rats and humans (Swerdlow et al., 1994, 2000). PPI is
reduced in psychiatric disorders such as acute psychotic mania in
bipolar disorder (Perry et al., 2001), ADHD (Hawk et al., 2003) and,predominantly, in schizophrenia (Braff et al., 2001; Geyer et al., 2001;
Weiss and Feldon, 2001).
In animals, PPI deﬁcits is produced by pharmacological stimuli
(Geyer et al., 2001) such as dopaminergic agonists or NMDA receptor
antagonists. Several studies have demonstrated that PPI deﬁcits in
animal models of schizophrenia display face, construct and predictive
validity (Swerdlow et al., 1994) and have been used to screen
antipsychotic efﬁcacy (Swerdlow and Geyer, 1998).
SHR have been suggested as a putative animal model of ADHD
(Russell, 2007; Sagvolden and Sergeant, 1998). This strain presents
behavioral characteristics of ADHD: it has sustained attention
problems, shows hyperactivity and impulsivity (Russell, 2007;
Sagvolden et al., 1992). Nevertheless, the absence of beneﬁcial effects
of psychostimulants (used to treat this disorder) on ADHD-like
behaviors in adult SHR (Bizot et al., 2007; Calzavara et al., 2009; Van
den Bergh et al., 2006) has been described. In fact, some behavioral
changes are even potentiated by these drugs (Calzavara et al., 2009).
In this regard, we have reported that SHR present a deﬁcit in
contextual fear conditioning that is speciﬁcally reverted by antipsy-
chotic drugs and potentiated by psychostimulants or other proschizo-
phrenia manipulations, such as ketamine administration and sleep
deprivation. It is important to note that procedures aimed to facilitate
learning were not able to improve this deﬁcit. This strain also does not
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et al., 2009). In this context, an absence of latent inhibition process has
been described for schizophrenia (Gray et al., 1992) and is one of the
most used paradigms to study attentional deﬁcits in animal models of
schizophrenia (Weiner, 2003). Theseﬁndings led us to suggest that the
deﬁcit in contextual fear conditioning of adult SHR could be a useful
animal model to study abnormalities in emotional context processing
related to schizophrenia (Calzavara et al., 2009). Furthermore,wehave
demonstrated recently that SHR present impaired social interaction
(that mimics negative symptoms of schizophrenia – Sams-Dodd,
1998; O'Tuathaigh et al., 2010) that is speciﬁcally ameliorated by
atypical antipsychotics (as seen in the clinic – Miyamoto et al., 2005)
and aggravated by amphetamine (Calzavara et al., 2011). In addition,
SHR display hyperlocomotion (that mimics positive symptoms of
schizophrenia – Powell and Miyakawa, 2006; Lipska and Weinberger,
2000) attenuated by antipsychotics and potentiated by amphetamine
(Calzavara et al., 2011). Finally, while the prevalence of tardive
dyskinesia, a late side effect of long-term treatment with antipsy-
chotics (Casey, 1987), is decreased in schizophrenia when compared
with affective disorders (Gardos and Cole, 1997), we have described
that SHR did not develop oral dyskinesia in animal models of tardive
dyskinesia (Abílio et al., 2004; Queiroz et al., 1998).
Parallel to that, it's noteworthy that previous studies describe
controversial results in relation to PPI in SHR. Some studies show that
SHR present PPI deﬁcits when compared to Wistar Kyoto (WKY)
(Ferguson and Cada, 2004; Kinkead et al., 2006), to Sprague-Dawley
(SD) (Ferguson and Cada, 2004) or to Lewis rats (Vendruscolo et al.,
2006). Conversely, other studies demonstrate that PPI tended to be
higher in SHR andWKY than in SD rats (Van den Buuse, 2004) or that
SHR has intermediate PPI values (Brown-NorwaybSHRbSDbWKY —
Palmer et al., 2000). However, methodological differences and the
absence of a pharmacological characterization complicate the inter-
pretation of these results.
In this context, the aim of the present work was to characterize PPI
response in the SHR strain. We evaluated the effects of the following
drugs administered previously to the PPI test: amphetamine (used for
ADHD and also a psychotomimetic drug), haloperidol and clozapine
(typical and atypical antipsychotics, respectively), metoclopramide
(dopamine antagonist without antipsychotic properties) and carba-
mazepine (a mood stabilizer).
2. Methods
2.1. Animals
MaleWistar rats (WR) and SHR, ﬁve-month-old, of our own colony
were housed under conditions of controlled temperature (22–23 °C)
and lighting (12/12 h light/dark cycle, lights on at 07:00 am). Groups
of 5 animals were kept in Plexiglas cages (41×34×16.5 cm), with free
access to food and water. The animals were maintained in accordance
with the guidelines of the Committee on Care and Use of Laboratory
Animal Resources, National Research Council, USA. This study was
approved by the Ethical Committee of Federal University of Sao Paulo.
All rats used were drug-naive before each experiment.
2.2. Drugs
Amphetamine (Sigma — St Louis, USA) and metoclopramide (Le
Petit — São Paulo, Brazil) were diluted in 0.9% saline. Haloperidol
(Sigma— St Louis, USA)was dissolved in lactic acid and then diluted in
distilled water. Clozapine (Novartis— São Paulo, Brazil) was dissolved
in acetic acid and then diluted in distilled water. Carbamazepine
(Sigma— St Louis, USA)was dissolved in Tween 80 and then diluted in
distillated water. Saline or distillated water plus acid lactic or Tween
were used as control solution depending on the drugs used in eachexperiment. All drug solutions were injected intraperitoneally (i.p.) in
a volume of 1 ml/kg body weight.
2.3. Apparatus
The rats were placed in a stabilimeter, which consisted of a wire-
mesh cage (16.5×5.1×7.6 cm) suspended within a PVC frame
(25×9×9 cm) attached to the response platform with four thumb-
nail-screws. The stabilimeter and platform were located inside a
ventilated plywood sound attenuating chamber (64×60×40 cm).
The ﬂoor of the stabilimiter consisted of six stainless steel bars 3.0 mm
in diameter and spaced 1.5 cm apart. The startle reaction of the rats
generated a pressure on the response platform and analogue signals
were ampliﬁed, digitized and analyzed by a software of the startle
measure system (Insight, São Paulo, Brazil), that also controlled other
parameters of the session (intensity of the acoustic stimulus, inter-
stimulus interval, etc.). Two loudspeakers located 10 cm above the
ﬂoor, on each lateral side of the acoustic isolation chamber, were used
to deliver the prepulse stimulus, the acoustic startle stimulus and
continuous background noise (65 dB). Calibration procedures were
conducted before the experiments to ensure equivalent sensitivities
of the response platforms over the test period.
2.4. Experimental procedure
The test session began by placing a subject in the stabilimeter cage
for a 5-min exposure to the background noise. After this acclimatiza-
tion period, the rats were presented with a series of 10 stimuli (pulse
alone — 120 dB, 50 ms duration), with an inter-trial interval of 20 s.
The purpose of this phase was to allow within-session habituation to
the startle stimulus. Thereafter, the PPI modulation of the acoustic
startle was tested in two different protocols. Protocol 1 (experiments
1, 3, 4 and 5): consisted of 60 trials pseudorandomly divided into four
different categories presented with an inter-trial interval of 20 s: 20
presentations of pulse alone (120 dB, 50 ms duration), 10 presenta-
tions of prepulse alone (75 dB, 3000 Hz frequency, 20 ms duration), 20
presentations of prepulse+pulse (with 50 ms interval) and 10 no
stimuli trials (stabilimeter recordings obtained when no stimulus was
presented) (adapted from Ross et al., 2008). Protocol 2 (experiment
2): consisted of 74 trials pseudorandomly divided into seven different
categories presented with an inter-trial interval of 20 s: 20 pre-
sentations of pulse alone (120 dB, 50 ms duration), 8 presentations of
each prepulse intensity alone (70,75 and 80 dB, 3000 Hz frequency,
20 ms duration) and 10 presentations of each prepulse intensity+
pulse (with 50 ms interval) (adapted from Gururajan et al., 2010).
All rats were submitted to a previous PPI session without drug
administration. After this session, called “matching” (Swerdlow et al.,
2005; Frau et al., 2007), rats were distributed into pharmacological
groups (vehicle or drug, for each experiment) matched for basal %PPI.
After seven days, each rat was submitted to a test session.
2.5. Experimental design
2.5.1. Experiment 1 — comparison of basal % PPI between WR and SHR
WR and SHR (n=9–10) were submitted to PPI test.
2.5.2. Experiment 2 — comparison of basal % PPI between WR and SHR
using a protocol with three prepulse intensities
WR and SHR (n=8–9) were submitted to PPI test using the
protocol with 3 different prepulse intensities (protocol 2).
2.5.3. Experiment 3 — effects of amphetamine on % PPI of WR and SHR
WR and SHR (n=8) were treated with vehicle (veh) or 5 mg/kg
amphetamine (amph). Fifteen minutes later, the rats were submitted
to the PPI test.
50
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%PPI of WR and SHR
WR and SHR (n=8) were treated with vehicle (veh), 0.1 mg/kg
haloperidol (halo) or 2.5 mg/kg clozapine (clo). Thirty minutes later,
the rats were submitted to the PPI test.
2.5.5. Experiment 5 — effects of carbamazepine (mood stabilizer) or
metoclopramide (D2 antagonist without antipsychotic properties) on
%PPI of WR and SHR
WR and SHR (n=9) were treated with vehicle (veh), 30 mg/kg
cabamazepine (carba) or 10 mg/kg metoclopramide (meto). Thirty
minutes later, the rats were submitted to the PPI test.
Based on the matching session, each animal was assigned to one
drug treatment and used only once.
Doses and schedules were chosen based on our previous studies
(Calzavara et al., 2009, Calzavara et al., 2011).
2.6. Statistical analysis
Mean amplitude of startle response to pulse-alone (P) and
prepulse-pulse (PP+P) trials were calculated for each subject. The
level of PPI in each rat was determined by expressing the prepulse+
pulse startle amplitude as a percentage decrease from pulse-alone
startle amplitude, according to the following formula:
%PPI=100− [100×(PP/P)]
Using this formula, a 0% value denotes no difference between
amplitude of startle response to pulse alone and to the prepulse+
pulse and, consequently, no PPI. Data were analyzed by Student's test
for comparisons between two groups (experiment 1), by a repeated
measures two-way ANOVA (strain×prepulse intensities) followed by
Paired-Samples T test (experiment 2), or by a two-way ANOVA (strain
x drug) followed by Duncan's test (experiments 3 ,4 and 5) and . The
pb0.05 was used as a criterion for statistical signiﬁcance.
3. Results
3.1. Experiment 1 — comparison of basal %PPI between WR and SHR
Student's T test indicated that SHR presented a signiﬁcant decrease
in PPI when compared with WR [t (17)=3.95; pb0.01] (Fig. 1).
3.2. Experiment 2 — comparison of basal % PPI between WR and SHR
using a protocol with three prepulse intensities
Repeated measures two-way ANOVA showed signiﬁcant effects of
prepulse intensities [F(2,30)=4.02; pb0.05] and strain [F(1,15)=
4.82; pb0.05]. SHR presented less PPI when compared to WR. Paired-
samples T test revealed that PPI with prepulse intensities of 75 and0
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Fig. 1. % PPI of Wistar rats (WR) and SHR. + pb0.05 compared to WR. Student's T test.
Data are reported as mean±S.E.80 dB was signiﬁcantly higher when compared to PPI with a prepulse
intensity of 70 dB (t=−2.27 and 2.45, pb0.05).
3.3. Experiment 3 — effects of amphetamine on % PPI in WR and SHR
Two-way ANOVA detected signiﬁcant strain [F(1,28)=7.75;
p≤0.01] and treatment [F(1,28)=9.11; p≤0.01] effects. SHRpresented
a signiﬁcant decrease in PPI when compared to WR. Amphetamine-
treated animals presented a signiﬁcant decrease in PPI when compared
to the vehicle-treated animals (Fig. 2).
3.4. Experiment 4 — effects of typical and atypical antipsychotics on %PPI
in WR and SHR
Two-way ANOVA detected signiﬁcant strain [F(1, 42)=21.05;
p≤0.01] and treatment [F(2, 42)=4.42; p≤0.05] effects. SHR pre-
sented a signiﬁcant decrease in PPI when compared to WR. Post hoc
analysis revealed that clozapine-treated animal showed a signiﬁcant
increase in PPI when compared to the vehicle-treated animals (Fig. 3).
3.5. Experiment 5 — effects of carbamazepine (mood stabilizer) and
metoclopramide (D2 antagonist without antipsychotic properties) on
%PPI in WR and SHR
Two-way ANOVA detected a signiﬁcant strain effect [F(1,48)=
20.47; p≤0.01]. SHR presented a signiﬁcant decrease in PPI when
compared to WR (Fig. 4).
4. Discussion
Our results demonstrate that SHR present a spontaneous deﬁcit in
PPI (experiment 1) that can be detected with different prepulse
intensities (experiment 2). This deﬁcit is similar to the deﬁcit induced
by amphetamine in Wistar rats (experiment 3). Only the atypical
antipsychotic clozapine reverted this deﬁcit (experiment 4).
Deﬁcits in sensorimotor gating, reﬂected by an impairment in PPI,
is presented in psychiatric disorders such as schizophrenia (Braff et al.,
2001; Geyer et al., 2001; Weiss and Feldon, 2001), bipolar disorder
(Perry et al., 2001) and ADHD (Hawk et al., 2003). In this sense, a
pharmacological characterization of the PPI deﬁcit presented by SHR is0
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Fig. 2. % PPI of Wistar rats (WR) and SHR using three different prepulse+pulse (PP)
intensities (70, 80 and 85 dB). + pb0.05 compared to WR. * pb0.05 when compared to
PP 70. Repeated measures two-way analysis of variance followed by paired-samples T
test. Data are reported as mean±S.E.
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Fig. 3. % PPI of Wistar rats (WR) and SHR treated with vehicle (veh) or 5 mg/kg
amphetamine (amph). * pb0.05 compared to vehicle-treated animals. + pb0.05
compared to WR. Two-way analysis of variance. Data are reported as mean±S.E.
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Fig. 5. %PPI of Wistar rats (WR) and SHR treated with vehicle, 30 mg/kg carbamazepine
(carba) or 10 mg/kg metoclopramide (meto). + pb0.05 compared to WR. Two-way
analysis of variance. Data are reported as mean±S.E.
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psychiatric disorders. Considering that SHR is suggested as an ADHD
model (Russell, 2007; Sagvolden and Sergeant, 1998) and that
amphetamine is recommended for its treatment, we tested this drug
on the PPI deﬁcit in SHR. Amphetamine was not able to ameliorate the
PPI deﬁcit presented by SHR (Fig. 3). In accordance, some studies have
also reported the absence of beneﬁcial effects of psychostimulants on
behavioral alterations presented by this strain (Bizot et al., 2007,
Calzavara et al., 2009; Ferguson et al., 2007;VandenBerghet al., 2006).
Amphetamine induced a disruption of PPI. This result corroborates
previous data (Geyer et al., 2001; Zhang et al., 2000). In this respect,
psychotomimetic agents, such as amphetamine, disrupt PPI in rodents
(Geyer et al., 2001), mimicking the sensoriomotor gating deﬁcit of
schizophrenia patients (Ong et al., 2005). In addition, a previous work
(Van den Buuse, 2004) using SHR and different control strains
demonstrated that a 10 times lower dose of amphetamine is able to
impair PPI in SHR (conversely to ours, in this study basal level of PPI in
SHR tended to be higher than in the other strains used). Interestingly,
the diminished PPI basal level in SHR is of the same magnitude than
the PPI observed in amphetamine-treated WR.0
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Fig. 4. % PPI of Wistar rats (WR) and SHR treated with vehicle (veh), 0.1 mg/kg
haloperidol (halo) or 2.5 mg/kg clozapine (clo). * pb0.05 compared to vehicle-treated
animals. + pb0.05 compared to WR. Two-way analysis of variance followed by
Duncan's test. Data are reported as mean±S.E.The PPI deﬁcits presented by SHR could be related to the PPI deﬁcits
presented by bipolar patients with acute psychotic mania (Perry et al.,
2001). If thiswas true, onemight expect that carbamazepine –which is
beneﬁcial to treat other symptoms of this disease – might ameliorate
the deﬁcit in PPI presented by SHR. Contrary to this possibility, this
drug did not alter the deﬁcit in PPI presented by this strain (Fig. 5).
Fewer studies have reported the effects of mood stabilizers on PPI in
rodents (Brody et al., 2003; Flood et al., 2009; Ong et al., 2005).
Speciﬁcally related to carbamazepine, Ong et al. (2005) showed that
50 mg/kg carbamazepine prevented ketamine-induced but not am-
phetamine-induced disruption of PPI in C57BL/6 J mice. Another study
(Flood et al., 2009) demonstrated that different doses of carbamazepine
increased percent PPI in theDBA/2mousemodel of naturally lowPPI. To
strengthen the ineffectiveness of carbamazepine on the PPI deﬁcit
displayed by SHR it would be interesting to test a dose–response curve.
On the basis of our previous data demonstrating that SHR present
deﬁcits in contextual fear conditioning and in social interaction that
are speciﬁcally reverted by antipsychotic drugs and potentiated by
psychostimulants (Calzavara et al., 2009; Calzavara et al., 2011), we
hypothesized that typical and atypical antipsychotics could also be
beneﬁcial for the PPI deﬁcits exhibited by this strain. Typical and
atypical antipsychotics are the conventional treatment for schizo-
phrenia but they do not demonstrate the same beneﬁcial effects for all
classes of symptoms (Miyamoto et al., 2005). Of note, the reduction in
PPI presented by SHR was signiﬁcantly improved only by the atypical
antipsychotic clozapine (the increase in PPI induced by clozapine is
independent of the strain) (Fig. 4). Our results are in accordance with
the clinical effectiveness of these drugs, particularly of atypical
antisychotics, in improving PPI deﬁcit in schizophrenia patients
(Hamm et al., 2001; Kumari and Sharma, 2002; Swerdlow et al.,
2006; Wynn et al., 2007). On the other hand, both typical and atypical
antipsychotics attenuate PPI deﬁcit in animal models using “proschi-
zophrenia” manipulations (Geyer et al., 2001; Swerdlow et al., 1994,
Weiss and Feldon, 2001). Hence, SHR seem to present an advantage
over these other models since this strain displays a greater sensitivity
to atypical antipsychotics for the PPI deﬁcits.
Although the beneﬁcial effect of clozapine in ameliorating PPI is in
accordance with the therapeutic proﬁle of antipsychotics in treating
schizophrenia-related PPI deﬁcits, this result could merely reﬂect
the modulatory effect of the dopamine neurotransmission on PPI
(Swerdlow et al., 2001). In order to verify this hypothesis, we
evaluated the effects of metoclopramide, a D2 antagonist without
antipsychotic activity. Corroborating the association of this deﬁcit
with schizophrenia-related sensorimotor gating impairment, the PPI
1752 R. Levin et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2011) 1748–1752deﬁcit in SHR was not reverted by this drug (although only one dose
was tested) (Fig. 5).
5. Conclusion
The spontaneous PPI deﬁcit presented by SHR was speciﬁcally
reverted by the atypical antipsychotic clozapine. In this sense, the
attenuation of PPI deﬁcits by antipsychotics is a hallmark of schizo-
phrenia animal models. Therefore, the beneﬁcial effects of clozapine
on the PPI deﬁcit presented by SHR add to our previous work
(Calzavara et al., 2009 and 2011) extending the usefulness of this
strain also to study sensorimotor gating abnormalities associatedwith
schizophrenia.
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